Correction: Phenylbutazone concentrations in synovial fluid following administration via intravenous regional limb perfusion in the forelimbs of six adult horses.

Phenylbutazone levels in the joint fluid of horses’ forelimbs were measured after the drug was administered using a targeted intravenous method to understand its distribution and potential effectiveness.

Study Objective and Background

• Investigate the concentration of phenylbutazone, a non-steroidal anti-inflammatory drug (NSAID), in synovial fluid after targeted delivery.
• Use intravenous regional limb perfusion (IVRLP), a technique to deliver drugs directly to a limb to maximize local drug concentration and minimize systemic exposure.
• Focus on forelimbs of adult horses to assess the potential for treating joint inflammation or pain locally.
• Correct prior publication information related to the study for accurate reference.

Methodology

• Subjects: Six adult horses were included in the study.
• Drug Administration: Phenylbutazone was administered via IVRLP to the forelimbs; this involves isolating the limb’s blood flow temporarily using a tourniquet to localize drug delivery.
• Sampling: Synovial fluid was collected from joints within the treated limb at specific time points post-administration to measure phenylbutazone concentration.
• Analytical Techniques: Pharmacokinetic analysis was conducted to assess drug concentration and distribution dynamics within the joint fluid.

Key Findings

• Phenylbutazone achieved measurable concentrations in synovial fluid after IVRLP, confirming the drug’s local delivery to the joint space.
• Concentration levels reached are relevant to therapeutic effectiveness, potentially improving treatment of joint conditions.
• The intravenous regional limb perfusion technique was demonstrated to be a feasible method for targeted anti-inflammatory therapy in equine forelimbs.

Implications and Conclusions

• IVRLP could offer a valuable clinical tool to enhance localized therapies in equine orthopedic medicine.
• Delivering phenylbutazone directly to the limb may reduce systemic side effects commonly associated with oral or systemic administration.
• Findings support further exploration of IVRLP for other drugs and conditions affecting distal limbs in horses.
• The correction notice emphasizes the importance of accurately citing and indexing the study for future research and clinical application.